InflaRx is a biotechnology company that discovers, develops, and commercializes anti-inflammatory therapeutics using proprietary technologies targeting the complement activation factor C5a and its receptor C5aR. The company operates through subsidiaries in Germany and the United States, conducting research and development of drug candidates for inflammatory diseases, with a focus on clinical development programs and preclinical studies. InflaRx funds its operations through equity offerings and explores potential partnerships to finance the advancement of its pipeline toward clinical trials.